<DOC>
	<DOCNO>NCT00591630</DOCNO>
	<brief_summary>The goal clinical research study learn addition 90Y Zevalin BEAM chemotherapy ( carmustine , etoposide , cytarabine , melphalan ) rituximab effective combination BEAM rituximab alone patient lymphoma receive stem cell transplant .</brief_summary>
	<brief_title>Zevalin/BEAM/Rituximab v BEAM/Rituximab With Without Rituximab Autologous Stem Cell Transplantation</brief_title>
	<detailed_description>The Study Drugs : 90Y Zevalin design attach lymphoma cell , destroy cell use radiation particle attach . 111In Zevalin like 90Y Zevalin , radioactive particle attach kill lymphoma cell . The radioactive particle make drug able see inside body . It use study predict fast study drug travel body long drug stay body . Carmustine , etoposide , cytarabine , melphalan ( BEAM ) design kill lymphoma cell damage cell DNA . Rituximab design attach lymphoma cell , may cause die . Study Groups 1 2 : If find eligible take part study , randomly assign ( toss coin ) 1 2 group . You equal chance assign group . Group 1 receive 90Y Zevalin along rituximab BEAM therapy . Group 2 receive rituximab BEAM therapy . You study staff know group . Study Drug Administration : If Group 1 , receive rituximab needle vein ( 4-5 hour ) follow 111In Zevalin vein ( 15 minute ) . A nuclear scan do within follow 40 48 hour see drug travel body . If intolerable side effect show scan , receive rituximab ( 4-5 hour ) 90Y Zevalin ( 15 minute ) needle vein 7 day 111In Zevalin infusion . You begin BEAM chemotherapy 7 day second 90Y Zevalin infusion . BEAM Chemotherapy : Both group 7 day BEAM combination chemotherapy . - On Day 1 , receive carmustine needle vein 1 hour . - On Days 2-5 receive cytarabine vein ( 1 hour ) follow etoposide ( 3 hour ) . Both infusion repeat every 12 hour Days 2-5 . - On Day 6 give melphalan vein 30 minute . - On Day 7 stem cell collect earlier give back ( `` transplant '' ) catheter 30-45 minute . - You also receive rituximab vein ( 5-7 hour ) Day 8 . You receive rituximab ( 4-5 hour ) 7 day stem cell transplant . You receive G-CSF injection day start 7 day stem cell transplant blood count return normal level . You stay Houston area 2-4 week transplant . Study Procedures : At 1 month transplant x-ray , CT scan , positron emission tomography ( PET ) scan . You also bone marrow aspirate biopsy check status disease . Blood ( 1 tablespoon ) drawn day hospital check blood count . Blood test ( 1-2 tablespoon ) , urine test , bone marrow collection , x-ray may do need track effect transplant . You transfusion blood platelet need . Study Groups A B : About 1 month transplant , randomly assign ( toss coin ) 1 2 new group ( Group A Group B ) . Group A receive rituximab vein 5-7 hour , every 3 month , start 3 month stem cell transplant . You receive rituximab first 18 month stem cell transplant . Group B receive rituximab . You equal chance group . Follow-up Visits : You return clinic every 6 month 5 year check status disease . The following test procedure perform : - Blood ( 1-2 tablespoon ) urine collect routine test . - You bone marrow biopsy check status disease . - You chest x-ray CT scan . - You PET scan . Length Study : You may stay study long benefitting . You take off-study disease get bad intolerable side effect occur . This investigational study . 90Y-Zevalin approved FDA relapse refractory lymphoma . Its use study investigational . 111In Zevalin , Carmustine , etoposide , cytarabine , melphalan , Rituximab FDA approve commercially available . However , use together study also investigational . Up 50 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Relapsed cluster differentiation antigen 20 ( CD20 ) positive Bcell diffuse large cell lymphoma ( demonstrated lymph node bone marrow ) , chemosensitive ( least PR ) . 2 . Age : 1870 year age . 3 . Prestudy performance status 0 , 1 , 2 accord WHO . 4 . No anticancer therapy start within three week , prior study initiation , fully recover toxicity associate prior surgery , radiation treatment , chemotherapy , immunotherapy . No prior rituximab within three week start therapy . 5 . If patient prior radiation , involve 25 % bone marrow . 6 . Acceptable hematologic status within two week prior patient registration , include : Absolute neutrophil count ( { segment neutrophil + band } x total WBC ) &gt; 1,500/mm³ platelet count &gt; 80,000/mm³ 7 . Institutional Review Board ( IRB ) approve sign informed consent . 8 . Patients determine &lt; 10 % bone marrow involvement lymphoma within 60 day study entry define bone marrow aspirate biopsy . 9 . Female patient include must pregnant lactating . 10 . Patients least 46 x 10^6 cluster differentiation 34 ( CD34 ) +/kg peripheral stem cell collect . Around 12 million cell behold back . 11 . Voluntary sign , write IRBapproved informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care . 12 . Men woman reproductive potential must agree follow accepted birth control method duration study . Female subject either postmenopausal surgically sterilize willing use acceptable method birth control ( i.e. , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study . Male subject agrees use acceptable method 1 . Failed stem cell collection &gt; /= 4x10^6CD34+/kg . 2 . Prior radioimmunotherapy . 3 . Presence active central nervous system ( CNS ) lymphoma . 4 . Patients abnormal liver function : total bilirubin &gt; 1.5 mg/dl . 5 . Patients abnormal renal function : serum creatinine &gt; 1.6 mg/dl . 6 . Serious nonmalignant disease infection , opinion investigator and/or sponsor , would compromise protocol objective . 7 . Corrected DLCO &lt; 50 % FEV subscript 1 FVC &lt; 50 % predict . 8 . Cardiac EF &lt; 50 % 2D Echogram . 9 . Prior radiation lung . 10 . Abnormal cytogenetics predictive secondary cancer , 5,7 . 11 . Pregnant ( Positive Beta HCG test woman child bear potential define postmenopausal 12 month previous surgical sterilization ) currently breastfeed . Pregnancy test require postmenopausal surgically sterilize woman . 12 . Patients malignancy diagnose within 2 year prior Study entry ( except skin squamous basal cell carcinoma ) . 13 . Active uncontrolled bacterial , viral fungal infection . 14 . Major surgical procedure significant traumatic injury within 4 week prior Study entry . 15 . Serious , nonhealing wound , ulcer , bone fracture . 16 . History abdominal fistula , gastrointestinal perforation intraabdominal abscess within 3 month prior Study entry . 17 . History Stroke within 6 month . 18 . Myocardial infarction within past 6 month prior Study Day 1 , New York Heart Association ( NYHA ) Class III IV heart failure arrythmias , unstable angina , uncontrolled congestive heart failure arrythmias , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , ECG abnormality screen must document investigator medically relevant . 19 . Uncontrolled chronic diarrhea . 20 . Serious medical psychiatric illness likely interfere participation clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Diffuse Large Cell Lymphoma</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Zevalin</keyword>
	<keyword>Ibritumomab</keyword>
	<keyword>IDEC-Y2B8</keyword>
	<keyword>Carmustine</keyword>
	<keyword>BCNU</keyword>
	<keyword>BiCNU</keyword>
	<keyword>Etoposide</keyword>
	<keyword>VePesid</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Ara-C</keyword>
	<keyword>Cytosar</keyword>
	<keyword>DepoCyt</keyword>
	<keyword>Cytosine arabinosine hydrochloride</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>BEAM</keyword>
</DOC>